메뉴 건너뛰기




Volumn 182, Issue 4 SUPPL., 2009, Pages 1378-1384

Pathological Effects of Prostate Cancer Correlate With Neuroendocrine Differentiation and PTEN Expression After Bicalutamide Monotherapy

Author keywords

bicalutamide; epidermal growth factor; prostatic neoplasms; PTEN phosphohydrolase; treatment failure

Indexed keywords

BICALUTAMIDE; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

EID: 69749104279     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.06.025     Document Type: Article
Times cited : (20)

References (21)
  • 1
    • 0021721387 scopus 로고
    • Leuprolide versus diethylstilbestrol for metastatic prostate cancer
    • Leuprolide Study Group
    • Garnick M.B., Glode L.M., and Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311 (1984) 1281
    • (1984) N Engl J Med , vol.311 , pp. 1281
    • Garnick, M.B.1    Glode, L.M.2
  • 2
    • 8544230666 scopus 로고    scopus 로고
    • Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells
    • Lee J.T., Steelman L.S., and McCubrey J.A. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64 (2004) 8397
    • (2004) Cancer Res , vol.64 , pp. 8397
    • Lee, J.T.1    Steelman, L.S.2    McCubrey, J.A.3
  • 3
    • 33745172528 scopus 로고    scopus 로고
    • The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice
    • Chen M.L., Xu P.Z., Peng X.D., et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice. Genes Dev 20 (2006) 1569
    • (2006) Genes Dev , vol.20 , pp. 1569
    • Chen, M.L.1    Xu, P.Z.2    Peng, X.D.3
  • 4
    • 0034808673 scopus 로고    scopus 로고
    • HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
    • Osman I., Scher H.I., Drobnjak M., et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7 (2001) 2643
    • (2001) Clin Cancer Res , vol.7 , pp. 2643
    • Osman, I.1    Scher, H.I.2    Drobnjak, M.3
  • 5
    • 0034833701 scopus 로고    scopus 로고
    • Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease
    • Shi Y., Brands F.H., Chatterjee S., et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166 (2001) 1514
    • (2001) J Urol , vol.166 , pp. 1514
    • Shi, Y.1    Brands, F.H.2    Chatterjee, S.3
  • 6
    • 12344252767 scopus 로고    scopus 로고
    • Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities
    • Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47 (2005) 147
    • (2005) Eur Urol , vol.47 , pp. 147
    • Vashchenko, N.1    Abrahamsson, P.A.2
  • 7
    • 12844287338 scopus 로고    scopus 로고
    • Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype
    • Evangelou A.I., Winter S.F., Huss W.J., et al. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 91 (2004) 671
    • (2004) J Cell Biochem , vol.91 , pp. 671
    • Evangelou, A.I.1    Winter, S.F.2    Huss, W.J.3
  • 8
    • 33744935016 scopus 로고    scopus 로고
    • Loss of PTEN is associated with progression to androgen independence
    • Bertram J., Peacock J.W., Fazli L., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 (2006) 895
    • (2006) Prostate , vol.66 , pp. 895
    • Bertram, J.1    Peacock, J.W.2    Fazli, L.3
  • 9
    • 0032431032 scopus 로고    scopus 로고
    • The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
    • Wu X., Senechal K., Neshat M.S., et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95 (1998) 15587
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 15587
    • Wu, X.1    Senechal, K.2    Neshat, M.S.3
  • 10
    • 0031961980 scopus 로고    scopus 로고
    • Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
    • Moscatello D.K., Holgado-Madruga M., Emlet D.R., et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273 (1998) 200
    • (1998) J Biol Chem , vol.273 , pp. 200
    • Moscatello, D.K.1    Holgado-Madruga, M.2    Emlet, D.R.3
  • 11
    • 33745255349 scopus 로고    scopus 로고
    • Androgen-dependent regulation of Her-2/neu in prostate cancer cells
    • Berger R., Lin D.I., Nieto M., et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66 (2006) 5723
    • (2006) Cancer Res , vol.66 , pp. 5723
    • Berger, R.1    Lin, D.I.2    Nieto, M.3
  • 12
    • 33947538812 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer
    • Wu C., and Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282 (2007) 3571
    • (2007) J Biol Chem , vol.282 , pp. 3571
    • Wu, C.1    Huang, J.2
  • 13
    • 33847258452 scopus 로고    scopus 로고
    • Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer
    • Wellington K., and Keam S.J. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer. Drugs Aging 24 (2007) 169
    • (2007) Drugs Aging , vol.24 , pp. 169
    • Wellington, K.1    Keam, S.J.2
  • 14
    • 0030890120 scopus 로고    scopus 로고
    • Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy
    • Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (1997) 16
    • (1997) Urology , vol.49 , pp. 16
    • Reuter, V.E.1
  • 15
    • 0023359813 scopus 로고
    • Cytological grading of therapy-induced tumor regression in prostatic carcinoma: proposal of a new system
    • Böcking A., and Auffermann W. Cytological grading of therapy-induced tumor regression in prostatic carcinoma: proposal of a new system. Diagn Cytopathol 3 (1987) 108
    • (1987) Diagn Cytopathol , vol.3 , pp. 108
    • Böcking, A.1    Auffermann, W.2
  • 16
    • 0022283210 scopus 로고
    • Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies
    • Helpap B. Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Appl Pathol 3 (1985) 230
    • (1985) Appl Pathol , vol.3 , pp. 230
    • Helpap, B.1
  • 17
    • 35948978956 scopus 로고    scopus 로고
    • Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer
    • Festuccia C., Gravina G.L., Muzi P., et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 14 (2007) 601
    • (2007) Endocr Relat Cancer , vol.14 , pp. 601
    • Festuccia, C.1    Gravina, G.L.2    Muzi, P.3
  • 18
    • 33845908460 scopus 로고    scopus 로고
    • Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?
    • Pendleton J., Pisters L.L., Nakamura K., et al. Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?. Urol Oncol 25 (2007) 11
    • (2007) Urol Oncol , vol.25 , pp. 11
    • Pendleton, J.1    Pisters, L.L.2    Nakamura, K.3
  • 19
    • 23944523430 scopus 로고    scopus 로고
    • The emerging role of the PI3-K-Akt pathway in prostate cancer progression
    • Li L., Ittmann M.M., Ayala G., et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8 (2005) 108
    • (2005) Prostate Cancer Prostatic Dis , vol.8 , pp. 108
    • Li, L.1    Ittmann, M.M.2    Ayala, G.3
  • 20
    • 27844506524 scopus 로고    scopus 로고
    • Akt-regulated pathways in prostate cancer
    • Majumder P.K., and Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 24 (2005) 7465
    • (2005) Oncogene , vol.24 , pp. 7465
    • Majumder, P.K.1    Sellers, W.R.2
  • 21
    • 0036847724 scopus 로고    scopus 로고
    • Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    • Di Lorenzo G., Tortora G., D'Armiento F.P., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 (2002) 3438
    • (2002) Clin Cancer Res , vol.8 , pp. 3438
    • Di Lorenzo, G.1    Tortora, G.2    D'Armiento, F.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.